A novel amphiphilic fluorescent probe BODIPY–O-CMC–cRGD as a biomarker and nanoparticle vector. Issue 36 (4th June 2018)

• Record Type: Journal Article
• Authors: Zhu, Tingting; Xiong, Ji; Xue, Zhongbo; Su, Yu; Sun, Fengnan; Chai, Ran; Xu, Jialiang; Feng, Yaqing; Meng, Shuxian
• Is Part Of: RSC advances. Volume 8:Issue 36(2018)
• Page Start: 20087
• Page End: 20094
• Publication Date: 2018-06-04
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/c8ra02125b
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : The amphipathic fluorescence probe, BODIPY– O -CMC–cRGD, can be applied in visualized diagnoses and as drug delivery vehicles of visualized therapies in the future. Abstract : Fluorescent probes have been demonstrated to be promising candidates as biomarkers and biological carriers. Our study focuses on the development of a novel amphiphilic fluorescent probe with good photostability, high water solubility, excellent specificity and promising loading capability for tumor diagnosis and treatment. At first, BODIPY dye and O -carboxymethyl chitosan were prepared via a chemical reaction. Then, the prepared BODIPY dye and cRGD were bonded to O -carboxymethyl chitosan successively via an acylation reaction. Finally, we obtained the desired amphiphilic fluorescent probe: BODIPY– O -CMC–cRGD, which was based on the fluorescence resonance energy transfer (FRET) principle for selective visualization of tumors in vitro . Through a series of experiments, we found that this fluorescent probe possessed better fluorescence characteristics and tumor targeting properties. Simultaneously, by self-assembly, the amphiphilic probe encapsulated the other flexible structure of BODIPY2 and the rigid structure of porphyrin, which formed distinct nanoparticles with different particle sizes. Hence, we could observe different phagocytosis processes of the two nanoparticles in the tumor cells via the fluorescence of dyes by confocal laser scanning microscopy. Therefore, the results suggest that the fluorescent probe has advantages in tumor detection, and the constructed tumor-specific nanoparticles show high clinical potential to be utilized not only in visual and precise diagnosis but also in excellent drug delivery for tumor treatment. Henceforth, we will prepare new targeted and visualized pharmaceuticals by replacing BODIPY2 and porphyrin with antineoplastic drugs for future tumor treatment.